Single nucleotide polymorphisms in the 20q13 amplicon genes in relation to breast cancer risk and clinical outcome.

Breast Cancer Res Treat 2011 Dec 1;130(3):905-16. Epub 2011 Jun 1.

Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, 69120 Heidelberg, Germany.

The 20q13 region is frequently amplified/overexpressed in breast tumours. However, the nature of this amplification/overexpression is unknown. Here, we investigated genetic variation in five 20q13 amplicon genes (MYBL2, AURKA, ZNF217, STK4 and PTPN1) and its impact on breast cancer (BC) susceptibility and clinical outcome. As a novel finding, four polymorphisms in STK4 (rs6017452, rs7271519) and AURKA (rs2273535, rs8173) associated with steroid hormone receptor status both in a Swedish population-based cohort of 783 BC cases and in a Polish familial/early onset cohort of 506 BC cases. In the joint analysis, the minor allele carriers of rs6017452 had more often hormone receptor positive tumours (OR 0.57, 95% CI 0.40-0.81), while homozygotes for the minor allele of rs7271519, rs2273535 and rs8173 had more often hormone receptor negative tumours (2.26, 1.30-3.39; 2.39, 1.14-5.01; 2.39, 1.19-4.80, respectively) than homozygotes for the common allele. BC-specific survival analysis of AURKA suggested that the Swedish carriers of the minor allele of rs16979877, rs2273535 and rs8173 might have a worse survival compared with the major homozygotes. The survival probabilities associated with the AURKA genotypes depended on the tumour phenotype. In the Swedish case-control study, associations with BC susceptibility were observed in a dominant model for three MYBL2 promoter polymorphisms (rs619289, P = 0.02; rs826943, P = 0.03 and rs826944, P = 0.02), two AURKA promoter polymorphisms (rs6064389, P = 0.04 and rs16979877, P = 0.02) and one 3'UTR polymorphism in ZNF217 (rs1056948, P = 0.01). In conclusion, our data confirmed the impact of the previously identified susceptibility locus and provided preliminary evidence for novel susceptibility variants in BC. We provided evidence for the first time that genetic variants at 20q13 may affect hormone receptor status in breast tumours and influence tumour aggressiveness and survival of the patients. Future studies are needed to confirm the prognostic value of our findings in the clinic.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-011-1600-5DOI Listing
December 2011
88 Reads

Publication Analysis

Top Keywords

hormone receptor
16
minor allele
12
rs2273535 rs8173
12
breast cancer
8
clinical outcome
8
breast tumours
8
receptor status
8
amplicon genes
8
promoter polymorphisms
8
20q13 amplicon
8
aurka
5
survival compared
4
worse survival
4
compared major
4
major homozygotes
4
confirm prognostic
4
rs8173 worse
4
allele rs16979877
4
carriers minor
4
rs16979877 rs2273535
4

References

(Supplied by CrossRef)

J Ferlay et al.
Int J Cancer 2010

I Soerjomataram et al.
Breast Cancer Res Treat 2008

JL Hopper et al.
Semin Cancer Biol 2001

K Hemminki et al.
Breast Cancer Res Treat 2009

M Hartman et al.
Breast Cancer Res 2007

K Hemminki et al.
Breast Cancer Res Treat 2008

M Kaufmann et al.
Cancer 2011

JD Mosley et al.
BMC Med Genomics 2008

A Sala et al.
Eur J Cancer 2005

ML Whitfield et al.
Nat Rev Cancer 2006

M Lauss et al.
Breast Cancer Res Treat 2008

Similar Publications